Opus Genetics Inc
NASDAQ:IRD

Watchlist Manager
Opus Genetics Inc Logo
Opus Genetics Inc
NASDAQ:IRD
Watchlist
Price: 2.31 USD -2.12%
Market Cap: 159.3m USD

Operating Margin
Opus Genetics Inc

-235.6%
Current
-102%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-235.6%
=
Operating Profit
-34.5m
/
Revenue
14.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Opus Genetics Inc
NASDAQ:IRD
152.3m USD
-236%
US
Eli Lilly and Co
NYSE:LLY
996.3B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
512.5B USD
27%
CH
Roche Holding AG
SIX:ROG
255.3B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.7B GBP
24%
CH
Novartis AG
SIX:NOVN
205.1B CHF
33%
US
Merck & Co Inc
NYSE:MRK
250.5B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
149B USD
29%
No Stocks Found

Opus Genetics Inc
Glance View

Market Cap
149.1m USD
Industry
Pharmaceuticals

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 14 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. Its pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and being evaluated in a Phase I/II open-label, dose-escalation trial, with advancing early data. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

IRD Intrinsic Value
0.63 USD
Overvaluation 73%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-235.6%
=
Operating Profit
-34.5m
/
Revenue
14.6m
What is the Operating Margin of Opus Genetics Inc?

Based on Opus Genetics Inc's most recent financial statements, the company has Operating Margin of -235.6%.

Back to Top